Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Hogan Lovells advises Perspective Therapeutics in its US$80 million underwritten offering of equity securities
Press releases
| 03
June
2024
Houston, Philadelphia, 3 June 2024 – Global law firm Hogan Lovells advised Perspective Therapeutics (NYSE AMERICAN: CATX) (“Perspective”) in an underwritten offering of 51,515,880 shares of its common stock at an offering price of US$1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price of US$1.509 per pre-funded warrant.
The gross proceeds from the offering were approximately US$80 million, before deducting underwriting discounts, commissions, and other offering expenses payable by Perspective in connection with the offering.
BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the offering and B. Riley Securities, Inc. acted as a co-manager. JonesTrading Institutional Services LLC acted as a financial advisor for the offering.
Perspective is a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Perspective has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
The Hogan Lovells team was led by partners Andrew Strong (Houston) and Stephen Nicolai (Philadelphia), senior associate Amanda Brown (Philadelphia), and associates Tyler Glass and Kayvon Paul (both Philadelphia), with assistance from partners Steve Abrams (Philadelphia), Steve Kaufman (Washington, D.C.), Michael Frank (Silicon Valley), and Nancy O’Neil (Baltimore), senior counsel Henry Kahn (Baltimore), and senior associate Elizabeth Adams (Washington, D.C.)
Press contacts
Press contacts
